Femasys (NASDAQ:FEMY – Get Free Report) is projected to post its Q3 2026 resultson Tuesday, November 17th. Analysts expect Femasys to announce earnings of ($0.6050) per share and revenue of $0.62 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.
Femasys (NASDAQ:FEMY – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.31) by ($0.02). The firm had revenue of $0.33 million during the quarter, compared to analysts’ expectations of $0.73 million. Femasys had a negative return on equity of 225.97% and a negative net margin of 534.36%.
Femasys Stock Performance
Shares of FEMY stock opened at $1.42 on Tuesday. Femasys has a 12-month low of $1.25 and a 12-month high of $22.20. The business’s fifty day simple moving average is $2.10 and its 200-day simple moving average is $5.84. The company has a current ratio of 2.14, a quick ratio of 0.55 and a debt-to-equity ratio of 0.89. The company has a market cap of $11.90 million, a PE ratio of -0.40 and a beta of -2.13.
Analysts Set New Price Targets
FEMY has been the topic of several research analyst reports. Lake Street Capital dropped their target price on Femasys to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, August 18th. Maxim Group lowered their price target on Femasys to $10.00 and set a “buy” rating for the company in a report on Friday, August 14th. Weiss Ratings downgraded Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. Finally, Wall Street Zen lowered Femasys from a “sell” rating to a “strong sell” rating in a research note on Sunday. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Femasys presently has an average rating of “Moderate Buy” and a consensus target price of $50.00.
Get Our Latest Stock Analysis on Femasys
Femasys Company Profile
Femasys Inc is a biotechnology and medical device company focused on developing and commercializing products for women’s health. The company’s portfolio is centered on solutions for permanent birth control, fertility evaluation and treatment, and related gynecological procedures.
Femasys’ products include FemVue, a device used with saline and air to assess fallopian tube patency during fertility evaluations. The company is also developing FemBloc, a non-surgical, investigational permanent birth control system designed for placement through the fallopian tubes.
Read More
- Five stocks we like better than Femasys
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.
